menu
    • menu
    [{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"9","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SYMYOO Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ Undisclosed"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SYMYOO Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ Undisclosed"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"GX-30","moa":"Thyroid stimulating hormone receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"7","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CDFR0612","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CDFR0812","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"8","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GC1113","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"6","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Immunoglobulin G","moa":"Immunoglobulin G (IgG)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SYMYOO Inc \/ SYMYOO Inc","highestDevelopmentStatusID":"6","companyTruncated":"SYMYOO Inc \/ SYMYOO Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by SYMYOO Inc

    Menu

    SYMYOO Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-30

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Recipient : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Pa...

                            Details : GX-30 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 08, 2017

                            Lead Product(s) : GX-30

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDFR0812

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : CTC Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation

                            Details : CDFR0812 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Premature Ejaculation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 08, 2015

                            Lead Product(s) : CDFR0812

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : CTC Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDFR0612

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : CTC Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy

                            Details : CDFR0612 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colonic Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 02, 2014

                            Lead Product(s) : CDFR0612

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : CTC Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : CTC Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males

                            Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 07, 2014

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : CTC Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of PED-1 in Male Patients With Premature Ejaculation

                            Details : Clomipramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Premature Ejaculation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2011

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GC1113

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin

                            Details : GC1113 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 02, 2011

                            Lead Product(s) : GC1113

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GCPGC in Chemotherapy-induced Neutropenia

                            Details : Pegfilgrastim is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Chemotherapy-induced Neutropenia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 05, 2011

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immunoglobulin G

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

                            Details : Immunoglobulin G is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sepsis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 15, 2011

                            Lead Product(s) : Immunoglobulin G

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation

                            Details : Clomipramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Premature Ejaculation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2010

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth